NCT03993626View on ClinicalTrials.gov

A Trial of CXD101 in Combination With Nivolumab in Patients With Metastatic Microsatellite-Stable Colorectal Cancer

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

May 22, 2018

Primary Completion Date

December 15, 2019

Study Completion Date

June 15, 2020

Conditions
Colorectal Neoplasms Malignant
Interventions
DRUG

CXD101 in Combination With Nivolumab

HDAC inhibitor in combination with anti-PD-1 monoclonal antibody

Trial Locations (1)

OX4 4GA

Celleron Therapeutics Ltd, Oxford

Sponsors
All Listed Sponsors
lead

Celleron Therapeutics Ltd.

INDUSTRY